liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes
Linköping University, Department of Biomedical Engineering, Medical Informatics. Linköping University, Faculty of Science & Engineering. CVMD iMed DMPK AstraZeneca R&D, Gothenburg, Sweden.
Eindhoven University of Technology, Eindhoven, The Netherlands.
AstraZeneca, Pharmaceuticals LP, Waltham, MA, USA.
AstraZeneca, Gothenburg, Sweden.
Show others and affiliations
2016 (English)In: Interface Focus, ISSN 2042-8898, E-ISSN 2042-8901, Vol. 6, no 2, 1-14 p.Article, review/survey (Refereed) Published
Abstract [en]

We are currently in the middle of a major shift in biomedical research: unprecedented and rapidly growing amounts of data may be obtained today, from in vitro, in vivo and clinical studies, at molecular, physiological and clinical levels. To make use of these large-scale, multi-level datasets, corresponding multi-level mathematical models are needed, i.e. models that simultaneously capture multiple layers of the biological, physiological and disease-level organization (also referred to as quantitative systems pharmacology-QSP-models). However, today's multi-level models are not yet embedded in end-usage applications, neither in drug research and development nor in the clinic. Given the expectations and claims made historically, this seemingly slow adoption may seem surprising. Therefore, we herein consider a specific example-type 2 diabetes-and critically review the current status and identify key remaining steps for these models to become mainstream in the future. This overview reveals how, today, we may use models to ask scientific questions concerning, e.g., the cellular origin of insulin resistance, and how this translates to the whole-body level and short-term meal responses. However, before these multi-level models can become truly useful, they need to be linked with the capabilities of other important existing models, in order to make them 'personalized' (e.g. specific to certain patient phenotypes) and capable of describing long-term disease progression. To be useful in drug development, it is also critical that the developed models and their underlying data and assumptions are easily accessible. For clinical end-usage, in addition, model links to decision-support systems combined with the engagement of other disciplines are needed to create user-friendly and cost-efficient software packages.

Place, publisher, year, edition, pages
London, UK: The Royal Society Publishing , 2016. Vol. 6, no 2, 1-14 p.
Keyword [en]
mathematical modelling, systems pharmacology, disease progression, decision-support type 2 diabetes, anti-diabetic treatment
National Category
URN: urn:nbn:se:liu:diva-127801DOI: 10.1098/rsfs.2015.0075ISI: 000375410900001PubMedID: 27051506OAI: diva2:927784

Funding agencies: Swedish Research Council; Swedish Diabetes Foundation; Linkoping Initiative within Life Science Technologies; CENIIT; Ostergotland County Council; EU [FP7-HEALTH-305707]; AstraZeneca

Available from: 2016-05-13 Created: 2016-05-13 Last updated: 2016-06-10Bibliographically approved

Open Access in DiVA

The full text will be freely available from 2017-02-19 00:00
Available from 2017-02-19 00:00

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Nyman, ElinStrålfors, PeterCedersund, Gunnar
By organisation
Medical InformaticsFaculty of Science & EngineeringDivision of Cell BiologyFaculty of Medicine and Health SciencesDepartment of Biomedical EngineeringDepartment of Clinical and Experimental Medicine
In the same journal
Interface Focus

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 231 hits
ReferencesLink to record
Permanent link

Direct link